Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.970
-0.030 (-3.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Akari Therapeutics, Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Akari Therapeutics,.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for AKTX.
Recommendation Trends
Rating | Jul '22 | Aug '22 | Sep '22 | Oct '22 | Nov '22 | Dec '22 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,992.78% | Dec 5, 2022 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +8,147.42% | Nov 1, 2022 |
B. Riley Securities | B. Riley Securities | Strong Buy Maintains $140 → $100 | Strong Buy | Maintains | $140 → $100 | +10,209.28% | Mar 13, 2020 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $160 | Strong Buy | Maintains | $300 → $160 | +16,394.85% | Mar 29, 2018 |
B. Riley Securities | B. Riley Securities | Hold Initiates $60 | Hold | Initiates | $60 | +6,085.57% | Feb 8, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.28M
EPS This Year
-3.47
from -2.04
EPS Next Year
-3.67
from -3.47
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | 4.4M |
Avg | n/a | 4.3M |
Low | n/a | 4.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | -3.57 | -3.78 |
Avg | -3.47 | -3.67 |
Low | -3.33 | -3.53 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.